francine: this is the man in charge of europe's most valuable company, novo nordisk, and its blockbuster diabetes and obesity drugs ozempic and wigovy, containing an ingredient revolutionizing the weight loss market and generating billions in sales. celebrities have helped their popularity soar. sharon osbourne and elon musk have all publicly talked about taking ozempic or wigovy, and have had further backing from oprah winfrey. it's a global phenomenon, reaching millions on social media apps including tiktok. but it is not without controversy, including possible side effects, high prices, and the company's lobbying efforts receiving criticism around the world. and in some cases, patients might also need to take the drugs indefinitely to avoid regaining weight. chief executive lars fruergaard jorgensen says obesity is a disease and thinks the company will learn from its growing number of patients. lars: they will tell you it is chronic treatment. my personal view is that patients are much different and there will be different avenues, so we will have to build a portfolio of interventions

it's a crucial market for weight loss drug makers like novo nordisk, but challenges remain.in the u.s. and the e.u. at the end of the next decade, and rival drugs are already emerging, like zepbound by eli lilly. i asked chief executive lars fruergaard jorgensen about regulatory pressures and future growth. so, how do you think about pricing? again, you must have gotten some difficult questions from governments, but also, this goes back to innovation. lars: most products are priced according to the value they bring. and i feel really good about the value of our medicines, what they bring to the individual patient, but also the value to the health care system. and we have today health care systems around the world who were typically designed for acute care. but finding that 80% of the cost in the health care system is linked to chronic care. and we have portfolio products that are really addressing some of the chronic diseases of our day and age. diabetes, obesity, and the comorbidities that follow that. we know that there are protections that say by 2035, the world obesity o

president, that hy the help committee has time and time again invited the leadership of novo nordisk these drugs in the united states.m@ and the reason why wet novo nor to testify before congress is not complicated. it is a very, very simple question that we want answered --. question is is why they think it is acceptable for novo nordisk to charge americans $969 for ozempic when that same exact drug can be purchased for just $59 in germany and $155 in canada? we want to ask them why they think it is acceptable to charge americans $1349 for wegovy when the same drug can be purchasedt kingdom. so,mr. president, aft all is said and done, what are we trying to accomplish? and the answer is the answer is simple -- we want novo nordisk to stop ripping off thewant them to sto charging us that are far, far higher than they charge the people of other countries. that is what i want to see, and that is what the overwhelming majority of american people want to see. unfortunately, despite the many, many discussions that i and my staff have had with novo nordisk over the past several months, i mus

and i really do want to congratulate the scientist at novo nordisk for their important work. i'm going to save lives all over the world but this product will mean nothing to an american was diabetes, we're dealing with obesity. if you cannot afford that product and that is the case. there are estimates out there the thousands of people will die unnecessarily simply because they cannot afford this product, which has sold so much more expensive in america than in other countries. second point if medicare and medicaid cover ozempic and wegovy there's going to be a huge increase in spending on those two-port important federal health insurance programs in fact, it's going to bankrupt medicare so we have got to get a handle on this. i have invited and he will come the ceo, mr. jorgensen, of novo nordisk, to come before the committee and simply explain why he thinks it's appropriate to charge us 15 times more than the people in germany or the uk? >> so obviously, i can't defend those, those prices and i'm not here to defend, but i do want to ask you a philosophical question because

novo nordisk plans to spend $4.1 billion to build a new factory in north carolina.n doubles the comedies production footprint in the u.s. the announcement sending the stock to a record high. joining us now is sarah. let's start with how much this will add when it comes to actually how much novo is able to ramp up its capacity to meet all that demand they are seeing. sarah: i think this is the key issue that novo is having. they are seeing such a big demand but they can't keep up with a capacity they have. this new factory will double the capacity in the u.s. but obviously, these things are not going to happen overnight. it is still a few years out before we get any pens out of the factory. it will not solve the problem immediately. this is something the investors are taking a positive note on because it will solve some of the problems. katie: even with that timeline, with to take a breath. it will take a while to see this boost to production coming. but you take a look at the share price, it is at a record high today. it is up 40% year-to-date over the past year or

about performance, prices get cheaper, the bigot ovation is obesity drugs in like eli lilly and novo nordiskonly eli lilly and novo nordisk for the last ten years and initially were excited about the diabetes franchise, they've taken the same medicines which are called glp-1's or incurred of invasive therapies and develop them for obesity and obesity is potentially the biggest market that i've ever seen in my career. to give you a sense, these products are already in utilizing out over $40 billion and growing over 35% as a first quarter, is widely expected this will be 100 billion-dollar market in the penetration if you look at the 800 million people that have obesity that are in the low single digit, huge growth opportunity ahead for these companies for the market leaders. jack: that's a very large tam total adjustable market, another company in the hunt not year that amgen that drug might be better than the competitors. >> first of all lily and novo are not standing still the goal is obsolete their own products with better products and as good as the products are today, historically we wou

it's a crucial market for weight loss drug makers like novo nordisk, but challenges remain. company's patents expire next year and rival drugs are already emerging like set down by eli lilly. i asked the chief executive about regulatory pressures and future growth. so how do you think about pricing? you must've gotten some difficult questions from government but also this goes back to innovation. >> most products are priced according to the value they bring and i feel really good about the value of our medicines, what they bring to the patient, but also the value to the health care system. and we have today, health care systems around the world to typically decide for acute care by finding that 80% of the system is linked to chronic care. we have portfolio products that are adjusting the chronic diseases of our day and age, diabetes, obesity, and the comorbidities that follow that. we know that there are protections that say by 2035, the world obesity federation protects the cost to society will be $4 trillion of people living with obesity. and that causes going to be taken

cnbc has reached out to novo nordisk for more details.ou see the shares are trading higher by 1.6%. still in the pharma space, merck has discontinued the trials of the cancer drug saying this would be unlikely to meet its primary objective. some of the announcement clearly not impacting shares to the possiblitive side. we are seeing them down almost 10%. when it comes to another company, covestro, they say they will target 400 million by 2028 with 190 million of that figure coming from germany. the savings will come from increased efficiency with digitalization and artificial intelligence. let's look at the u.s. futures and understand how the session on wall street is shaping up. you can see on your screen that we are tracking basically a soft start to the session on wall street. looking slightly positive at this stage. when it comes to the economic events that we are monitoring today out of the united states, it includes consumer confidence which is due today. on top of that, we will hear from fed officials as well including michelle bow

like i said, novo nordisk is a significant push higher.hat's why you see tech and healthcare at the top end of the counter. utilities and telecoms out of step with the market going down on that front. industrials and household goods managing to move higher. of course, the market will focus on the ecb decision. >>> on to the u.s. futures here. it looks like we could be on for benign moves from the stateside move after yesterday's move higher with intraday records. nasdaq moving 2%. nvidia sucking the a.i. out of the market climbing 5%. speaking of nvidia, this is pretty much the stock we will all focus on. that's been the behemoth that's really moved higher then. we are looking at asml. 2.3% higher. taiwan semiconductor up 5%. the reason why is the chip demand story which continues to move higher. analysts and investors are not just looking at where nvidia is right now. looking at where to from here and that growth has really been very significant and important for markets. you could have added applied materials to the market as well then t

now we've got this, novo nordisk, they are the famous makers of ozempic and wegovy. for some competition. all right, who is the new competitor? lauren: china. literally, all of china. they have a dozen companies working on yes fleshes. imagine that, china -- generics. china doing the copycat thing. here's the deal, novo nordisk loses the patent on the active ingredient in ozempic and wegovy in china in 2026. so it's soon. and the local drug makers are already -- half a billion people in china are overweight. just overweight. and then another 150 million plus are obese, and goldman sachs is saying that the generics could bring down the brand price by 25%. stuart: wow. and mow slow nor disk and eli lilly still a little bit higher this morning. microsoft. okay, i've got a thin sliver of that, the stock is down a fraction this morning. they're being investigated by the ftc. lauren because of a $65500 million licensing deal $650 million licensing deal. "the wall street journal" is reporting that the ftc -- both companies. regulators want to know how this deal was structur

. >> novo nordisk gets the green light in china and eli lilly in the pharma battle next. high rolling highfliers. delta air lines flashing the cash an a-list luxury lound in one of the busiest airports and will the glitz and glam be enough to keep frequent fliers happy? we'll pop this cork on the trade next. you're watching "fast money" from the nasdaq marketsite in times square. we're back right after this. ew . to help you see untapped possibilities and relentlessly work with you to make them real. [thunder rumbles] ♪ ♪ ♪ ♪ the biggest ideas inspire new ones. 30 years ago, state street created an etf that inspired the world to invest differently. it still does. what can you do with spy? ♪ ♪ [thunder rumbles] ♪ ♪ >>> welcome back to "fast money." novo nordisk gaining 3% after wegovy was approved in china for long-term weight management after it announced a $4.9 million investment in wegovy manufacturing capacity here in the united states. also in pharma, eli lilly saying it will work with open ai to develop novel treatments for drug resistant bacteria. both lilly and nov

you looking at some of the movers of novo nordisk. >> morgan stanley reiterates dell as a topic theynd thinkers momentum and the a.i. servers in the pc rebound, the stock is up almost 3%. stuart: i saw micron up. >> cantor fitz-gerald ghost wanted $80 a share 20% upside from the last close thanks to the a.i. boom they report next week and cantor says watch their margins strong pricing of the chips could lead to a 40% gross margin as soon as august, that would be a win. stuart: news from apple supplier. >> apple is up $3 now 1.7% tdk japanese supplier says that has a battery rate through a solid-state battery capable of holding more aimed at air pods smart watches, air tax, devices smaller than the iphone. thank you the doctor who blew a whistle on the texas children's hospital faces a judges afternoon. he said the hospital provided gender affirming care for minors even after they claimed the program would be shut down, nate foy joins me why is the whistleblower facing charges. >> because he released this redacted information, today at 3:00 o'clock eastern time, the doctor will appear

ozempic, et cetera the 30-60 day wait, love amir been taken off the market by novo nordisk's so we needive the inhaled insulin has been on the market beers already and it hasn't really been used but what was really clever about this study at the university of washington as it puts together with a baseline shot you get one a day and you can use the inhale when you have meals performed bedtime so it cuts down dramatically your need for any kind of injection. so i think this could be a game changer facing this insulin shortage when there was a cap on medicare for out-of-pocket expenses for insulin under the inflation reduction act but has not been extended to young diabetics, type one diabetics who live and die by their insulin. >> sandra: this is from the foxnews.com piece that breaks down this study and it says researchers evaluated the results of 141 adults, doctor, who were said to use this inhaler, went on the market fda approval in 2014 so ten years now who are including pump delivery with the inhaled insulin group 30% of participants reach their target glucose levels compared to 17%

novo nordisk are going to build a new manufacturing facility in north carolina. with demand. lauren: it's crazy stocks up 2%. they need to boost their manufacturing so they are spending $4.1 billion to expand their north carolina factory in the next five years so this will not be immediate. the other thing and this is helping the stock is wagovy was just approved in china and that's a big deal because of china's population, they have the most obese people in the entire world. the worldwide market for the weight loss drugs is estimated to hit $100 billion by 2030. i mean, there's patent issues in china obviously but it opens up the market for them. stuart: these weight loss drugs and a.i. have burst on to the market. lauren: new technology. stuart: it's real revolutions. enormous amounts of money have poured in. that's the great thing about america. they can attract capital to new ideas. a.i. has attracted $1 trillion in capital input only in america can you get that. lauren: but novo nordisk is a european company. stuart: don't spoil my argument. lauren: although

also the competitor novo-nordisk. the gl-1s are just getting started. larger. liz: it is getting larger. in fact lily had some positive results for one of its therapies for weight loss and talk about that and why you think this could really be great for stuffing the channel at least for more customers? >> yeah, you're going to see a lot more benefits than you know, every drug you have out there has a risk but there is a lot more upside if it is applied properly such as for the here as well as diabetes and also some positive news came out helping dementia patients. the gamut is running larger and larger. it is five billion total addressable market today. it is 100 approximately. that will make eli lilly a trillion dollar company before you know it. liz: eli lilly is nvidia and as well as novo-nordisk of the weight loss drugs. give me your macro picture. what will serve as the catalyst for the second half? >> right now it is coming down to earnings. the first-quarter earnings were, we saw positive earning growth from the s&p 500. you will want to stick wi

mientras novo nordisk, fabricante de y seÑalÓ que hacen todo lo posible para asegurar que los pacientesdas, adquirirlos Únicamente con una receta de un mÉdico y comprobar siempre el envase y la fecha de caducidad. erika flores noticias telemundo. >> ahora hablemos de polÍtica. el expresidente donald trump se mostrÓ a favor de dar la residencia permanente a los extranjeros graduados en las universidades de aquÍ de estados unidos. incluso sugiriÓ que deberÍan obtener la green card automÁticamente con su diploma o tÍtulo universitario. lo dijo durante una entrevista para un podcast publicado hoy, agregando que ha conocido a muchos graduados con buenos planes de negocios que han tenido que volver a sus paÍses empleando a miles de personas, pudiendo haberlo hecho aquÍ. este martes, el presidente biden comentÓ algo similar al anunciar que planea acelerar las visas de trabajo para ciertos inmigrantes graduados en universidades de estados unidos. hoy comenzÓ oficialmente el verano en el hemisferio norte y aquÍ serÁ o bueno, fue el dÍa mÁs largo del aÑo y serÁ la noche mÁs corta. a las 16:51 de

francine: this is the man in charge of europe's most valuable company, novo nordisk, and its blockbustertes and obesity drugs ozempic and wegovy.

francine: this is the man in charge of europe's most valuable company, novo nordisk, and its blockb

. >>> the drug company, novo nordisk says it's building a new plant in north carolina.rease the supply of popular weight loss drugs like wegovy and ozempic. the new plant is expected to open between 2027 and 2029. >>> paramount plus is the latest streamer to announce price hikes. the subscription will showtime will increase by a dollar a month, making it $12.99. the essential paramount plus plan will rise by two dollars. >>> and walmart is taking on prime day. they teased some deals with markdowns on things like electronics and back-to-school items. it runs from july 8 to july 11. we'll be right back. we'll be ri. did you know... 80% of women are struggling with hair damage? just like i was. dryness and frizz could be damaged hair that can't retain moisture. new pantene miracle rescue deep conditioner, with first-of-its-kind melting pro-v pearls... locks in moisture to repair 6 months of damage in one wash, without weigh down. guaranteed or your money back! for resilient, healthy-looking hair... if you know, you know it's pantene. a mystery! jessie loves playing detecti

. >> a spokesperson for novo nordisk, the makers of ozempic say that the company is working with the to crackdown on the counterfeits. some members of congress say high drug prices are to blame the fueling the black market and want more regulation of drug companies. that includes south bay congressman ro khanna. he's supporting a bill that would direct drugmakers to lower prices to be on par with other countries. and if they don't, the government could approve cheaper generic versions regardless of patents in place. still ahead, why tesla's cybertruck is facing yet another recall. >> nearly 300 types of canned coffee products distributed nationwide are being recalled over botulism concerns. the fda says wisconsin based company snap chill llc, recall their products after learning their manufacturing process could lead to the potentially deadly food poisoning. botulism can cause weakness, dizziness, double vision, and trouble speaking or swallowing, no illnesses have been reported from the coffee so far. and tesla's new cybertruck being recalled again this time to fix issues with trim

the danish pharma group novo nordisk has said it will spend $4.1 billion to build a new manufacturingrolina. the expansion is aimed at boosting the supply of its blockbuster weight—loss drugs. demand for wegovy and ozempic has outstripped supply over the last year, leading to some shortages in the us. 0n on to other events taking place here in the uk today. japan's emperor naruhito will be formally welcomed by king charles and queen camilla for a state visit today. the emperor will be given the full pomp and pageantry of state occasions, welcomed at horse guards parade followed by a carriage procession to buckingham palace for a state banquet. the visit comes at a time when the uk is seeking to bolster trade ties with japan. the japanese economy has been struggling with inflation and a weak yen, losing its position as the world's third—largest economy to germany last year. john nilsson—wright is the head of the japan and korea's program at the centre for geopolitics at the university of cambridge. 0utline why this state occasion is so important for both japan and the uk. 50 is so impo

now, you've heard of the most valuable novo nordisk, because you may take one of its products, including ozempic, and you've almost certainly heard of the third biggest, lvmh. although if that doesn't sound familiar, it's brands will sephora, moet and chandon, louis vuitton, among others. which leaves us with asml. it makes things that make chips, specifically lithography. the etching of patterns on silicon wafers. and though the company has a thousand employees in silicon valley, it happens worldwide, worldwide, rather, ralph howell is a vice president of research and development for the company. so this is the second most valuable company in europe. i believe it's a dutch company, right. but i don't think most people, rafe, have ever heard of it. right so we like to think of ourselves as the most important technology company that you have never heard of. but indeed, we are a multinational company. we're headquartered in the netherlands. but sites worldwide, including here in the states, and we are a leading supplier in the semiconductor industry. this is the industry that manufactures

novo nordisk's plans to invest 4.1 billion u.s. dollars. of its obesity and diabetes drugs. the project in north carolina will double the company's production footprint in the u.s. adding manufacturing space where their medicines will be filled in to inject the pins and prepare for consumers. the facility will create a thousand jobs. it's entering formal terms with adnoc on a takeover that could value the chemical company at about 11.7 billion euros. the middle east and energy giant indicated that it is considering a potential offer of 62 euros per share subject to due diligence, the final deal would represent the biggest ever acquisition. traders are warning the japanese yen could weaken to its lowest level against the u.s. dollar nearly 40 years, some asset manager said the yen could trade at 170 per dollar. on monday for japan's vice finance ministers said authorities are ready to intervene 24 hours a day to prevent wild fluctuations. you have warned for a while that the pressure on the annual pension -- will continue because the rate di

. >> and trying to find a market leader across europe yes, fine, you look at novo nordisk and you thinko yourself, lvmh and the granolas as a whole where would you find direction in europe? this is where you need to invest if i'm not from europe and i'm looking to europe and looking to get in right now, where does one go >> well, i think just in general, there's the european outlook is slightly more favorable than last year i think if we look -- >> that is looking at isolation, not comparing to china or the u.s. that would give you a distorted view. >> that's true if we compare the eurozone and european economy compared to the u.s., that is under performance. our view this year is we will see a bit of a convergence and actually if we look at the european economy, say to relative to last year, there is a lot of scope to the upside f. we look at the u.s., strong growth there last year, we are seeing signs of deterioration that convergence should be good for european assets in general >> any sectors you are looking at specifically? >> not particularly. as a currency company, we take a broa

trade, the significant shift higher, the granola, the ones like gsk and the likes of novo nordisk asell in all that, haven't been able to necessarily push up the market across europe in the last month or so. in the last quarter, muted gains with .25% so far. it still adding on what we get on today's market movement. for the half year, gains of 7.29% is what we are seeing for the stoxx 600. is this still enough value in this market to see gains? yesterday, speaking to maximilian from deutsche bank r saying there were gains to be found. that is an important factor for you out there as well. compare then to the united states, it gives you a clear sentiment that the united states is up double what you are getting out of that one. here you are 15% ultimately is what you are getting out of the s&p 500. again, it has been the tech or a.i. trade, really, that has pushed things on quite significantly. in terms of all those gains and losses, that is perhaps what you will be looking out for. to find the sectors moving up outside of technology is the tougher part as well. is it technology or com

>> i'll pick it up there we're also getting some news from novo nordisk? tell us about that >> they're telling us they will spend $4.1 billion to build a new glp-1 manufacturing base here in the u.s. this will focus on making wegov and future drugs for obesity this is one of the largest manufacturing investments in its history. we're seeing an arms race between novo and lilly as they try to make as many of their glp drugs as they possibly can novo telling us that about 35,000 people in the u.s. are starting wegovy over week. that's up from 27,000 in may but it's important to remember that these sites take years to get up and running, so we won't see this investment have an effect right away. guys >> thanks very much. ang angelica, appreciate it. >> you got it. >>> still to come, the eu adopting new sanctions against russia, even on lng. that story is next hi, i'm sally. i'm from phoenix, arizona. i'm a flight nurse on a helicopter that specializes in trauma. i've been doing flight nursing for 24 years. i had a fear that i wouldn't be able to keep up. i wan

even just focusing on european drug companies it tends to get less coverage than novo nordisk or evenrugmakers like roche and novartis. but this company has a much stronger story. for starters it's got an amazing oncology franchise, among the best in the business. remember we interviewed their ceo last week? the company released three important daytona sets that the big american society of clinical oncology conference got a standing ovation for one. we're talking positive phase 3 daytona on two different lung cancer drugs and a breast cancer drug, potential blockbusters. they got the daytona ota. this reduced risk of disease progression or death by an astounding 84% in patients with a specific type of nonsmall cell lung cancer. no wonder it got a standing "o." insane number that can save a lot of lives and affects 15% of american was get the disease and, well, for many it's a death sentence. but maybe not now. by the way we've had updates on the research since the conference. last monday they said they got a recommendation from a key committee in the european medicine agency saying it

the company that makes the drug is novo nordisk and they studied man and women with the common heart the patients for women. the other half men, women lost an average of 9 and a half percent of their weight during the study, man lost about 7%. scientists. not sure yet why the women did do better in that regard. and the man. while millions of people across the country are enduring sweltering temperatures, parts of the midwest are recovering from a weekend of severe storms and flooding. a state of emergency has been declared in south dakota where officials say at least one person died in flood waters, minnesota, iowa also very hard hit by intense rain. some buildings almost completely submerged and a tornado was confirmed in northern michigan and making matters worse. more storms are expected across the region in the coming days. kron meteorologist dave spahr. as back i've talked to a lot of friends across the country. a lot of them suffering from the heat. yes. the coverage area of that is pretty impressive. at the same time, katherine, of all that you're talking about. here's the big

stuart: i've got a buck that says novo nordisk is up, because lauren: wagovy was approved in china andause of its population they have the highest number, most obese people in the entire world. stuart: nobody would believe that. lauren: i know it's kind of shocking. stuart: don't expect that, frankly but there you are. what about google? lauren: new high. waymo, self-driving, open to everybody. is in the city of san francisco. there is no wait list. all you have to do is download the app and put it in your destination. stuart: i'd like to do that. i would like to try that. lauren: you could blast the music as loud as you want. you don't have to worry about anybody else in the car. i frankly like to worry about people in the car, specifically a driver at the steering wheel. stuart: i wonder if we could get fox news on the tesla in san francisco. that be an interesting question. i'll try. lauren, thank you. coming up a new white house official had thousands of social media posts mocking republicans criticizing israel and comparing police to slave patrols but those posts seem to have disa

novo nordisk, what's this about illegal shipment coming to america? small dollar or imimportants. ozempic is joining a soaring number of illegal medications entering the u.s. through the e-commerce sales. people are trying to buy the weight loss drug at a lower cost, but the concern is if you're buying this from a source that's not regulated by the fd -- fda, you could get really sick. stuart: the stock is down 1.2%. delta, again, an interesting story. they're launching a premium economy service on some upcoming flights. tell me, what is premium economy? >> all right. so, basically, the group between economy and business class, and it really offer as you more choice. you're going to get more leg room, noise-canceling headphones maybe if there's a baby nearby, a full meal and a blanket. and this is going to be basically on the new york to l.a. flights. it's part of a broader push by airlines to upsell. you're seeing more options for lounge access, premium seating while overall a air a fare slips. these companies are trying to capitalize and focus willi

and just in the past hour vermont senator bernie sanders issuing a press release announcing novo nordisk'senate committee on the cost of glp-1 drugs. the at a time date of the hearing is not specified but this is an issue that senator sanders has been pursuing vehemently. >>> well, gilead getting today topping the tape up 3.5%. the pharma company putting out pre-clinical test results on oral glp-1 drug ahead of next week's american diabetes association meeting. the data showing participants losing an average of 6.5% of their body weight over 36 days in line with the results from eli lilly's oral glp in trial. the one potential snag, gilead's study was conducted in monkeys, not humans, the participants were monkeys, not known where whether those monkeys had diabetes either. you laugh at that. but, i mean, it's important to know if some of these differences. >> bananas are high in sugar. >> potassium. >> well, potassium. >> you're noting today on the call, tim, that gilead has just been kind of a dog. >> it's been more than a dog. and i know when our clever team when they write the intro cop

all right, novo nordisk.r weight loss drug we geoff with i have in china -- wegovy. why would they do that? lauren lauren because there's a lot of obese people in china, literally, they have the world's largest -- they won't be able to meet demand. and let's say they can give all of the people who want it in china a couple of doses. can they keep fulfilling those doses and also the balancing act, right? what about supply for folks in other countries? a final point. there are -- there's generic competition in china bigtime for wegovy. their patent expires in 2026 which is much sooner than in other countries. so maybe they want to get it out faster before the generics come online. i'm not sure. stuart: will chinese consumers sent chinese-made weight loss drugs as opposed to the foreign-made novo -- lauren: they have to pay out of pocket. under no circumstances will chinese health care companies pay for this. stuart: i can see it coming. levis, down 16%. what's the -- lauren: i don't get it. denim is so in right

company that makes the drug is novo nordisk.men? other half are men. one last an average of 9 and a half percent of their weight during the study. then last about 7% of their body weight. scientists are not sure why women at greater benefits than men. 7.50, right now. and in sports, the giants honor willie mays at oracle park starting their series against the cubs. as sports director jason dumas says all those highlights. obviously then a mentally exhausting week. but you've got to keep all pushing, just like this, say, hey, kid. >> would have done himself. san francisco will have a more formal celebration of life for willie later in the season. but they still gave their respect. they honored him pre-game all players from both of those teams were wearing number. 24 barry bonds, the godson of willie mays was also in attendance along with whaley son michael. it was a moment of silence. a nice gesture for one of the most transcendent athletes of all time. we pick things up in the top of the 5th cubs up a run. men on the corners. co